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Summary
Effectiveness
Evidence comes from 3 large
multicentre randomised controlled
trials, 1 single centre randomised
controlled trial and 1 large register.
Three systematic reviews,
4 randomised controlled trials and
1 large cohort study indicate that
the PressureWire devices can be
effective as adjuncts to coronary
angiography to identify functionally
significant stenosis.
In patients with stable coronary
artery disease and fractional flow
reserve (FFR) of less than 0.8,
outcomes were better for FFR-
guided percutaneous coronary
intervention (PCI) than for medical
treatment alone.
Adverse events and safety
An FFR-guided strategy, compared with an
angiography-guided approach, resulted in no
statistically significant difference in relative risk
reduction for major adverse cardiac event
outcomes.
In 1 randomised controlled trial, major adverse
cardiac events were significantly improved by
FFR-guided PCI at 1 year, but the difference was
not significant at 2 years. There were significantly
fewer myocardial infarction events in the FFR-
guided PCI group at 2 years than in the
angiography group.
Copyright © NICE 2014. All rights reserved. Last updated 04 February 2014 Page 1 of 54
Costs and resource use
The PressureWire Aeris costs
£598.80 and PressureWire Certus
(with Agile tip) costs £499. Each
PressureWire FFR device is single
use.
Four economic analyses evaluated
FFR guided-strategies using the
PressureWire FFR devices, but no
published economic analyses
based in the UK were identified.
Technical factors
PressureWire FFR devices are used by
interventional cardiologists in a cardiac
catheterisation laboratory setting.
The PressureWire Certus device is used with the
Quantien proprietary monitor unit (St Jude
Medical), purchased separately; the
PressureWire Aeris device uses wireless
transmission to a receiver unit connected to
monitoring platforms with FFR capability.
Key points
The PressureWire Aeris and PressureWire Certus (with Agile Tip) fractional flow reserve (FFR)
devices are intended to measure the functional stenosis in a coronary artery, to help with
treatment decisions in coronary artery disease and evaluate effectiveness of treatment. The
PressureWire FFR devices have been compared against coronary angiography in clinical
studies.
Evidence from 3 systematic reviews, 4 randomised controlled trials and 1 large cohort study
indicates the PressureWire devices can be effective as adjuncts to coronary angiography to
identify functionally significant stenosis, to help determine the best treatment for people with
coronary artery disease.
Four economic analyses evaluated FFR guided-strategies using the PressureWire FFR devices.
However, they did not directly address whether using the devices would be cost effective in the
NHS.
Introduction
Coronary heart disease causes around 94,000 deaths each year in the UK (Ludman 2013a,b).
Atherosclerosis is a disease process in which fat accumulates in the coronary arteries leading to
fatty plaques that are visible on angiogram.
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Stable angina occurs when the blood flow to the heart is restricted by a narrowing of the
coronary arteries. It causes chest pain after physical exercise or stress. There is a risk that it may
lead to acute coronary syndrome, including unstable angina and myocardial infarction. In
myocardial infarction the blood flow in a coronary artery is blocked for long enough that the heart
muscle it supplies starts to die. In ST elevation myocardial infarction (STEMI), the vessel remains
blocked, whereas in non-ST elevation myocardial infarction (NSTEMI) flow is spontaneously re-
established so that ST elevation does not occur. The pathology for the 2 syndromes is the same
but STEMI needs to be treated more urgently. Unstable angina is new onset angina (usually
within 24 hours) or abrupt deterioration in previously stable angina, often occurring at rest.
Technology overview
This briefing describes the regulated use of the technology for the indication specified, in the
setting described, and with any other specific equipment referred to. It is the responsibility of
healthcare professionals to check the regulatory status of any intended use of the technology in
other indications and settings.
About the technology
CE marking
Two PressureWire fractional flow reserve (FFR) devices (St Jude Medical) are currently
available: PressureWire Aeris and PressureWire Certus (with Agile Tip). Both are class III
medical devices and received CE marking in 2009 and 2012 respectively.
Intended use
The PressureWire FFR devices measure FFR, a physiological parameter used to assess the
severity of stenoses in the coronary arteries. This briefing describes the use of PressureWire
FFR devices in the investigation of stenoses in coronary arteries. In this context they are
designed to determine whether a stenosis detected during angiography is functionally significant
(that is, causes ischaemia). FFR can potentially inform the decision about whether to perform
revascularisation, and on which lesions, or manage the symptoms conservatively with medical
therapy.
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The PressureWire FFR devices may also be used in assessing blood flow after stent placement
and in investigating renal arteries. These uses are within the intended use of the device and
covered by the CE mark, but are outside the scope of this briefing.
Setting and intended user
The PressureWire FFR devices are used by interventional cardiologists in a cardiac
catheterisation laboratory setting, during diagnostic angiography or percutaneous coronary
interventions (PCI).
Description
Angiography is an X-ray based imaging technique that uses a contrast agent to visualise
narrowing (stenosis) in the coronary arteries that may be responsible for cardiac ischaemia.
Angiography uses a percutaneous catheter introduced to the coronary arteries via a peripheral
artery (femoral or radial), and guided by a guidewire.
PCI involves treating coronary artery narrowing by balloon angioplasty, with or without the use of
a stent, under angiography. Coronary artery bypass grafting (CABG) may be necessary in severe
cases.
The PressureWire Certus (with Agile tip) and Aeris devices are guidewires with a diameter of
0.014 inch and a sensor element at the tip. The Certus device is used with the Quantien
proprietary monitor unit (St Jude Medical), purchased separately, whereas the Aeris uses
wireless transmission to a receiver unit connected to monitoring platforms with FFR capability.
During PCI, the PressureWire FFR device and catheter are moved through the arterial system.
The PressureWire FFR device can then be directed until the sensor tip is distal to the lesion of
interest, recording arterial pressures both proximal and distal to the stenosis, enabling the FFR to
be calculated.
The measurement takes place under artificially induced conditions of maximal blood flow
(hyperaemia). This is usually achieved by injection of a drug such as adenosine. Under these
conditions coronary blood pressure is proportional to blood flow, and the ratio of pressure before
and after the stenosis is equivalent to the ratio of flow. FFR is defined as the distal coronary
artery pressure divided by the proximal coronary artery pressure.
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Lesions with an FFR of 0.80 or less are indicated for revascularisation in several guidelines
(Montalescot et al. 2013; Patel et al. 2012; Wijns et al. 2010). There is significant inter-operator
variability in the visual assessment of coronary stenoses (Carrick et al. 2011; Hoole et al. 2011),
but very severe or very mild stenoses are less uncertain. FFR measurement is typically used in
determining the functional significance of intermediate lesions (for example, 40–70% stenosis).
Current NHS options
Diagnostic angiography is currently the standard method used in the NHS if invasive
investigation is needed to assess the severity of coronary artery disease. Angiography uses a
catheter. A guidewire with FFR capability may be introduced subsequently into the catheter, or
may be used for both the conventional guidewire function and pressure measurement.
NICE is aware of the following CE marked device that appears to fulfil a similar function:
FloWire Doppler guidewire (Volcano Corporation)
Alternative investigations to determine whether to perform revascularisation include non-invasive
testing, such as exercise tolerance testing, dobutamine stress echocardiography, myocardial
perfusion imaging using radionuclides and magnetic resonance perfusion imaging. Intravascular
ultrasound allows the true dimensions of the lesion and the composition of the vessel wall to be
visualised (Dawkins et al. 2005).
Data from the British Cardiovascular Intervention Society indicate that in 2012, 13,762 FFR
procedures were carried out compared with 6407 intravascular ultrasound procedures (during
both diagnostic angiography and PCI; Ludman 2013a).
Costs and use of the technology
Each PressureWire FFR device is single use. A Quantien monitor (St Jude Medical) is also
needed to use the PressureWire Certus (with Agile tip). The PressureWire Aeris device can also
be used with a Quantien monitor (which includes the wireless receiver unit), or the receiver unit
can be bought separately to allow the use of another monitoring platform with FFR capability.
The monitors and receiver units can be used more than once.
The list prices of the PressureWire FFR devices, excluding VAT, are:
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PressureWire Aeris – £598.80
Aeris receiver unit – £399 (only necessary if the Quantien monitor is not purchased)
PressureWire Certus (with Agile tip) – £499
Quantien monitor – £22,500
1 year full service contract – £1000
2 year service contract – £1499.99.
Cables to connect to the catheterisation laboratory monitors are likely to cost from £100 to
£300 each depending on the system used.
Maximal hyperaemia is needed to correctly measure FFR. This is most often achieved by giving
adenosine intravenously or by intracoronary bolus. The measurement of FFR takes an extra
5–20 minutes during the angiography and there is a significant degree of technical skill and
knowledge needed to ensure that pressure measurements from both the PressureWire FFR
device and catheter are accurate. However, these should be within the standard competencies of
an experienced interventional cardiologist.
Likely place in therapy
FFR is used for diagnostic testing and to guide treatment decisions.
The NICE clinical guideline on stable angina (NICE clinical guideline 126) states that patients
should normally be treated medically. However, for people whose symptoms are not satisfactorily
controlled with optimal medical treatment, coronary angiography to guide treatment strategy
should be considered. Treatments may include revascularisation by PCI or coronary artery
bypass surgery (CABG). The guideline states 'Additional non-invasive or invasive functional
testing may be required to evaluate angiographic findings and guide treatment decisions'.
A 2011 study abstract reported that, in a UK regional cardiology centre, the indication for FFR
measurement in people with NSTEMI was an 'intermediate coronary lesion (that is, 40– 80%
stenosis severity) associated with diagnostic and treatment uncertainty' (Carrick et al. 2013).
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The European Society of Cardiology guideline on the management of stable coronary artery
disease indicates that 'FFR is recommended to identify hemodynamically relevant coronary
lesion(s) when evidence of ischaemia is not available' and 'revascularization of stenoses with
FFR <0.80 is recommended in patients with angina symptoms or a positive stress test'
(Montalescot et al. 2013).
The American College of Cardiology issued guidelines in 2012 indicating the different situations
in which using FFR for assessing lesion severity was appropriate, and the level of certainty. It
also indicated that 'in patients without previous non-invasive imaging, or patients in whom the
prior testing is not in concordance with the symptoms or angiographic findings......for lesions
between 50% to 69%, invasive FFR is the test preferred for diagnostic purposes' (Patel et al.
2012; Patel 2013).
Specialist commentator comments
Measurement of FFR is already part of the pathway in some centres for people referred for PCI,
when there is uncertainty about the significance of stenosis from non-invasive imaging. It is
estimated that 10–18% of people referred for PCI currently have FFR measured. There is
agreement that it could be used more widely, including in different settings such as diagnostic-
only cardiac catheterisation laboratories in addition to those capable of performing PCI, and as a
decision tool for people referred for CABG, for whom PCI may be suitable.
Barriers for wider use are the cost per use, additional time per procedure, a perceived or actual
lack of expertise, and whether cardiac catheterisation laboratories can be organised to perform
FFR measurement.
Evidence review
Clinical and technical evidence
Regulatory bodies
The Medicines and Healthcare products Regulatory Agency (MHRA) website reports 1 product
recall notice issued on 16 September 2011. The alert advised users that a specific batch of
PressureWire Aeris could produce erroneously low fractional flow reserve (FFR) values because
of a production fault, and that this batch should not be used.
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The USA Food and Drugs Authority (FDA) database, Manufacturer and User Device Facility
Experience (MAUDE) reports 54 relevant records. Records in MAUDE are entered from a variety
of sources, may contain duplicates and the accuracy has not been verified. Where details were
available they included incidents of the wire or tip of the device breaking during use, and
dissection or perforation during the procedure. No search was made for information on other
guidewire devices.
Systematic reviews
Three systematic reviews in English were identified: Raman et al. (2013), Blue Cross and Blue
Shield (2011) and Medical Services Advisory Committee (MSAC, 2005). A further systematic
review, Siebert et al. (2008) was excluded as the full text was available only in German. A list of
the papers included in each is in table 8. Note that the systematic reviews did not select for
named devices and therefore may include data relating to FFR devices other than PressureWire
FFR devices.
Raman et al. (2013)
This peer-reviewed comparative effectiveness review was carried out for the Agency for
Healthcare Research and Quality (AHRQ) in the USA (Raman et al. 2013). It focused on
5 questions, the first of which was the impact of using an intravascular diagnostic technique with
angiography versus angiography alone to make therapeutic decisions, and subsequent
intermediate outcomes and patient-centred outcomes. The other questions looked at were not
relevant to this briefing.
Evidence included 1 randomised controlled trial (FAME) and 2 non-randomised studies
(Muramatsu et al. 2002; Wongpraparut et al. 2005). The DEFER trial was excluded because it
'examined appropriateness of stenting a functionally non-significant stenosis, and did not
compare FFR-guided stenting versus stenting guided by angiography alone'. It should be noted
that other systematic reviews have included this trial and it is summarised later in this briefing.
The FAME II trial was excluded because 'all patients underwent FFR during angiography, and
FFR-guided stenting plus optimal medical therapy was compared with optimal medical therapy
only.'
The reviewers assessed the risk of bias for the included studies as: FAME: low, Wongpraparut
et al. (2005): medium, and Muramatsu et al. (2002): high. Study results were summarised in
narrative form only.
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The report found a moderate strength of evidence favouring FFR-guided stenting decisions over
stent placement decisions guided by angiography alone, in patients with intermediate coronary
lesions.
Blue Cross and Blue Shield (2011)
This US assessment aimed to review and evaluate available evidence comparing outcomes
following FFR-guided percutaneous coronary intervention (PCI) against PCI guided by
angiography alone in patients with angina (Blue Cross and Blue Shield Association Technology
Evaluation Center 2011).
Evidence included 2 randomised controlled trials (DEFER and FAME) and 4 observational
studies (Chamuleau et al. 2002; Legalery et al. 2005; Lindstaedt et al. 2006; Wongpraparut et al.
2005). Excluded studies were not listed.
The authors found that trial data were consistent and that results from the small observational
studies were in agreement, although with limitations inherent in observational data. They noted
the use of bare metal stents and single target vessels in the DEFER trial. They also noted that
there were large numbers of moderate severity lesions in the FAME trial, where PCI in the
angiography alone arm was based on physician judgement, including any non-invasive testing.
The authors concluded that the evidence suggested that identifying stenoses is insufficient to
determine if revascularisation is likely to be of benefit. For patients with angina for whom
revascularisation is considered, evidence suggests that FFR-guided PCI results in better
outcomes than strategy guided by angiography alone.
Medical Services Advisory Committee (MSAC, 2005)
This assessment was published by the MSAC in Australia. The scope included the measurement
of FFR and coronary flow reserve for single or multi-vessel coronary artery disease, for
intermediate lesions (coronary stenosis 30–70%) and post-angioplasty or stenting.
Evidence included:
2 randomised controlled trials (Bech et al. 2001a; Leesar et al. 2003)
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8 non-randomised studies in patients with a range of FFR levels (Bech et al. 2001b; Botman
et al. 2004; Jasti et al. 2004; Jimenez-Navarro et al. 2004; Lopez-Palop et al. 2004; Reczuch
et al. 2004; Rieber et al. 2002)
4 non-randomised studies, in patients with FFR levels considered functionally non-significant
(Bech et al. 1998; Hernandez-Garcia et al. 2001; Meuwissen et al. 2003; Ozdemir et al.
2002)
1 study comparing FFR to a triple stress test (Pijls et al. 1996).
DEFER (Bech et al. 2001a) is described in full in this briefing.
The report also analysed studies in subgroups.
For single-lesion disease the studies were consistent with the DEFER findings, that for patients
with a FFR of 0.75 or more there was with no overall difference in major cardiac events if PCI
was carried out or deferred.
For left main coronary artery disease, 3 observational studies found improvements in angina
status after FFR measurement regardless of intervention, but this should be treated with caution
due to the observational nature of the studies.
For multiple lesion disease 3 observational studies were compared, but no overall conclusions
were drawn.
There were no studies restricted to myocardial infarction or unstable angina. Leesar et al. (2003)
studied a population with unstable angina or non ST-segment elevated myocardial infarction
(NSTEMI), but the 2 groups could not be separated out.
The report's recommendations were accepted by the Australian Minister for Health and Ageing:
'On the strength of evidence relating to safety, effectiveness and cost-effectiveness, the MSAC
recommends that public funding be supported for the use of coronary pressure wires to
determine whether revascularisation should be performed on intermediate lesions identified on
coronary angiography, where previous stress testing has either not been performed or the results
are inconclusive'.
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Randomised controlled trials
Four randomised controlled trials (10 papers) were identified. Their design is summarised in
table 1 and the key findings described in following text and tables.
Table 1: Summary of randomised controlled trial protocols
Study
component
Description
DEFER FAME FAME II Dambrink (2010),
Ghani (2012)
Population Stable
angina,
referred for
elective PCI
Multi-vessel CAD,
PCI indicated
Stable CAD, eligible
for PCI
STEMI, already
successfully
treated with PCI
Treatment
before
randomisation
Randomise
first to PCI
or defer,
then FFR
for all
Angiogram to
assess need for
PCI, then
randomise to
receive FFR
Angiogram to
assess need for
PCI then FFR for
all. Randomise
where FFR
significant
All patients had
STEMI and
successful PCI for
culprit lesion in
previous 3 weeks
Arm 1 Significant +
PCI
FFR guided PCI Significant,
PCI+medical
FFR guided PCI
Arm 2 Not
significant +
defer
Angiogram guided
PCI
Significant, medical Conservative
treatment
Arm 3 Not
significant +
PCI
N/A Not significant,
medical
N/A
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What would
have been
standard care
for these
patients?
All patients
would have
received
PCI
Patients would
have received
angiography
guided PCI
Patients would
have received
angiography guided
PCI
Patients would
have received
medical treatment
Randomisation Yes, but
method not
stated
Yes, sealed
envelope, blocks
of 25.
Yes, stratified by
site, random block
sizes
Yes, computer
program, no other
detail given
Blinded
treatment
Not stated Not stated No Not stated
Blinded
outcomes
Not stated,
Events
reviewed by
independent
committee
Events
adjudicated by
independent
committee who
were unaware of
treatment
Events adjudicated
by independent
committee who
were unaware of
treatment
Blinded for
echocardiographic
and radio nuclide
outcomes.
CAD, coronary artery disease; FFR, fractional flow reserve; PCI, percutaneous coronary
intervention; STEMI, myocardial infarction with ST-segment elevation.
DEFER study
This multicentre randomised controlled trial was carried out in 12 hospitals in Europe and
2 hospitals in Asia between June 1997 and December 1998 (Bech et al. 2001a; Pijls et al. 2007).
The pressure wire devices used were from RADI Medical Systems, the previous manufacturer of
the PressureWire devices.
The DEFER trial treatment groups, and outcomes, are described in tables 2 and 3.
Event-free survival for all patients with functionally non-significant stenosis (PERFORM plus
DEFER) was 76% (p=0.03). For patients with functionally non-significant stenosis, 21% of
PERFORM and 27% of DEFER experienced 1 or more events at 5 years. In the reference group
this was 39% (p=0.03 compared with the combined PERFORM plus DEFER).
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In this trial, for patients with stable chest pain and functionally non-significant stenosis
(FFR≥0.75), stenting did not improve outcomes. Measuring FFR could therefore help to identify
patients who would not benefit from stenting.
Table 2: Summary of the DEFER trial a
Study
component
Description
Objectives/
hypotheses
Is PCI justified in patients with stable chest pain and a functionally non-
significant coronary stenosis?
Study
design
Multicentre, prospective randomised controlled trial
Setting 12 hospitals in Europe and 2 hospitals in Asia between June 1997 and
December 1998
Clinical follow-up was at hospital discharge and after 1, 3, 6, 12, 24 and
60 months
Patients were randomised to PCI or deferral of PCI. All patients then
underwent FFR measurement. In both arms patients with FFR<0.75 received
PCI, and these formed the REFERENCE group. In the performance of PCI
arm, patients with FFR
≥0.75 received PCI and were labelled the PERFORM group. In the deferral of
PCI arm, patients with FFR≥0.75 did not receive PCI and were labelled the
DEFER group
Stents were bare metal stents
Inclusion /
exclusion
criteria
Inclusion criteria
Referral for elective PCI of a single angiographically significant stenosis
(>50%) in native coronary artery with reference diameter >2.5mm
No evidence of reversible ischaemia in last 2 months
Exclusion criteria
Total occlusion of target artery
Acute Q-wave infarction
Unstable angina with transient ST-segment abnormality
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Variables Primary outcome was freedom from adverse cardiac events (MACE) after
2 years of follow-up
Statistical
methods
No sample size calculation was given.
Intention to treat analysis
Baseline characteristics were compared using chi-square test or unpaired
student t-tests
Kaplan-Meier survival curves for absence of adverse cardiac events and
compared by the log rank test
P<0.05 was considered significant. All tests were 2-tailed
Participants There were more men than women in the study, and statistically significantly
more men in the reference group (80%) than in the FFR≥0.75 group (65%
DEFER, 63% PERFORM), p<0.05. Statistically significantly more non-invasive
stress tests were performed in the FFR≥0.75 group (67%) than in the
reference group (53%), and statistically significantly more negative results
were seen (47% DEFER, 50% PERFORM) than in the REFERENCE group
(31%). Age, ejection fraction, clinical history and angina class did not show
significant differences
Main results The primary end point of event-free survival in patients at 2 years was 89% in
the DEFER group, and 83% in the PERFORM group (p=0.27). Event free
survival of the reference group was 78% (PERFORM p=0.31, DEFER p=0.03)
Event free survival at 5 years was 79% in the DEFER group, and 71% in the
PERFORM group (p=0.52). Event free survival of the reference group was
61%. (PERFORM p=0.17, DEFER not reported)
Event free survival for all patients with functionally non-significant stenosis
(PERFORM+DEFER) was 76% (p=0.03)
Conclusions For patients with stable chest pain, where FFR≥0.75, stenting did not improve
outcomes
CI, confidence interval; FFR, fractional flow reserve; ITT, intention to treat; n, number of
patients; PCI, percutaneous interventions; RR, relative risk.
a The table contains information from several papers concerning the same DEFER RCT.
These are: Bech et al. (2001a, 2 year results), Pijls et al. (2007, 5 year results).
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Table 3: Results of the DEFER trial a
DEFER
Group
PERFORM
group
REFERENCE
group
Analysis
Randomised n=91 n=90 n=144
Efficacy n=91
1 lost
at
5 year
n=90
2 lost at
5 year
n=144
10 lost at
5 year
ITT
Primary
outcome: event-
free survival at
2 years
89.0%
(80/91)
83.3% (75/
90)
78.4% (106/
144)
% and numbers given as reported,
but % are not as calculated from
numbers.
p=0.27, 95% CI −15.7% to 4.6%
(DEFER:PERFORM)
p=0.31 (REF:PERFOM)
p=0.03 (REF:DEFER)
Selected
secondary
outcomes
Event-free
survival at
5 years
79%
(72/91)
71% (64/
90)
61% (88/144) p=0.52 (DEFER:PERFORM)
p=0.17 (REF:PERFORM)
p=0.03 (REF:DEFER+PERFORM)
Cardiac death 3.3%
(3/91)
2.3% (2/
90)
6.0% (8/144)
Other death 3.3%
(3/91)
3.4% (3/
90)
3% (4/144)
MI (Q wave and
non Q wave)
0 6.7% (6/
90)
9.0% (13/
144)
Freedom from
angina
67%
(61/91)
57% (51/
90)
72% (104/
144)
p=0.028 (REF:DEFER+PERFORM)
p=0.015 (Reference:Perform)
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Safety n=91 n=90 n=144
Total adverse
events
21 30 70 Reported as 'total events after
5 years'. Patients may have had
more than 1 event
Patients with
≥1 event
21%
(19/91)
27% (24/
90)
39% (52/144) p=0.03 (REF:DEFER+PERFORM)
CABG 1.1%
(1/91)
4.5% (4/
90)
10.4% (14/
144)
TVR 8.9%
(8/91)
9.1% (8/
90)
13.4% (18/
144)
Non-TVR 6.7%
(6/91)
6.8% (6/
90)
8.2% (11/
144)
% and numbers given as reported,
but % are not as calculated from
numbers
Other 0% (0/
91)
1.1% (1/
90)
1.5% (2/144)
CABG, coronary artery bypass graft; CI, confidence interval; ITT, intention to treat; MI,
myocardial infarction; n, number of patients; RR, relative risk; TVR, tricuspid valve
replacement.
a The table contains information from several papers concerning the same DEFER
randomised controlled trial. These are: Bech et al (2001a), 2 year results), Pijls et al. (2007,
5 year results).
FAME study
FAME was a multicentre randomised controlled trial across 5 medical centres in the USA and
15 in Europe between January 2006 and September 2007 (Fearon et al. 2007; Fearon et al.
2010; Pijls et al. 2010; Tonino et al. 2009). FAME compared the clinical outcomes and cost
effectiveness of treatment based on measurement of FFR using the pressure wire devices from
RADI Medical Systems (in addition to angiography) against treatment guided by angiography
only, in patients with multi-vessel coronary artery disease for whom PCI was appropriate.
A summary of the trial is presented in tables 4 and 5.
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The study showed that measuring FFR in patients with multi-vessel coronary artery disease
having PCI with drug-eluting stents significantly reduces myocardial infarction (MI) at 2 years
when compared with standard angiography-guided PCI.
Four papers were identified that reported subgroup analyses of the FAME trial (Kim et al. 2012;
Nam et al. 2011; Sels et al. 2011; Tonino et al. 2010), 2 of which are relevant to this briefing. A
major limitation for any subsequent analysis was that the study was designed and powered to
examine the original study question only, so conclusions should be treated with caution.
Sels et al. (2011) reanalysed the trial data to determine if there was a difference in benefit of FFR
guidance for PCI for patients with unstable angina or NSTEMI (n=328), compared with stable
angina (n=677). The absolute risk reduction from using FFR guidance compared with
angiography guidance was similar (5.1% unstable angina or NSTEMI, 3.7% stable angina,
p=0.922). The authors noted that FFR measurement can be limited by microvascular
obstructions that are often present with MI, but that the FAME study population was defined to
minimise this issue.
Kim et al. (2012) considered the impact of sex differences on FFR-guided PCI using data from
the FAME study, with 744 men and 261 women. They found that the proportion of functionally
significant lesions was lower in women than in men for lesions with 50–70% stenosis (21.1%
compared with 39.5% respectively, p<0.001). They also reported that the FFR-guided strategy
resulted in no statistically significant difference in relative risk reduction for major adverse cardiac
event (MACE) type outcomes for men and women, compared with an angiography-guided
approach.
Table 4: Summary of the FAME study a (2 year results)
Study
component
Description
Objectives /
hypotheses
To compare the clinical outcomes and cost-effectiveness of treatment based
on measurement of FFR in addition to angiography against treatment guided
solely by angiography in patients with multi-vessel coronary artery disease for
whom PCI is appropriate
Study
design
Multicentre randomised controlled trial
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Setting 5 medical centres in the USA and 15 in Europe between January 2006 and
September 2007
Clinical follow-up was at 1 year for primary outcomes, and at 30 days,
6 months, 2 years and 5 years for secondary outcomes
The patients were assessed for PCI by using angiogram, then randomised to
the FFR or angiogram arm. For the FFR-guided strategy, the clinician could
only stent if FFR≤0.8. 96.9% of stents were drug-eluting stents
Inclusion /
exclusion
criteria
Inclusion criteria:
Multi-vessel coronary artery disease (≥ 50% diameter stenosis in ≥2 major
epicardial vessels) and PCI indicated.
Age ≥18 years
Exclusion criteria:
Previous coronary bypass surgery
Left main coronary disease
Recent ST elevation MI (<5 days)
Recent non-ST elevation MI (<5 days) if peak CK is
>1000 U per litre
Cardiogenic shock
Extremely tortuous or calcified coronary vessels
Life expectancy <2 years
Pregnancy
Contraindicated for placement of drug-eluting stent
Variables Primary outcome was the rate of major adverse cardiac events at 1 year,
defined as a composite of death, MI and repeat revascularisation
Secondary outcomes measured at 30 days, 6 months, 2 years and 5 years
The PressureWire fractional flow reserve measurement system
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Statistical
methods
Sample size based on: 426 patients in each arm, based on alpha level 0.05,
statistical power of 0.8 assuming adverse cardiac events at 1 year of 14% for
angiography and 8% for FFR.
Intention to treat analysis
Categorical variables compared using chi-square test, continuous variables
compared with unpaired t-test or Mann-Whitney U test.
Kaplan-Meier curves for time-to-event distribution of primary end point
Participants Baseline characteristics of the 2 groups are reported as similar, as were the
number of indicated lesions and angiographic extent and severity of CAD. In
both groups there were more men than women (angiography 73% male; FFR
75% male)
Main results The primary outcome, MACE at 1 year, occurred in 91 patients (18.3%) in the
angiography-guided group, and 62 patients (13.2%) in the FFR group (P=0.02)
MACE at 2 years occurred in 111 patients (22.4%) in the angiography-guided
group, and 91 patients (17.9%) in the FFR group (p=0.08)
Conclusions The primary outcome (MACE) was significantly improved by FFR-guided PCI
at 1 year, but the difference was not significant at 2 years. There were
significantly fewer MI events in the FFR-guided PCI group at 2 years than in
the angiography group
CI, confidence interval; ITT, intention to treat; MACE, major adverse cardiac event; MI,
myocardial infarction; n, number of patients; PCI, percutaneous coronary intervention; RR,
relative risk.
a The table contains information from several papers concerning the same FAME RCT.
These are: Fearon et al. (2007, study design, Tonino et al. (2009, 1 year results), Pijls et al.
(2010, 2 year results).
Table 5: Results of the FAME study a (2 year results)
Angiography FFR Analysis
Randomised n=496 n=509
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Efficacy
At 1 year
At 2 years
n=496
11 lost
36 lost
n=509
8 lost
29 lost
ITT
p=0.45
p=0.31
Efficacy n=496
36 lost
n=509
29 lost
ITT
p=0.31
Primary
outcome: MACE
at 1 year
18.3% (91/
496)
13.2%
(62/509)
p=0.02,
RR=0.72
95% CI 0.54–0.96
MACE at
2 years
22.4% (111/
496)
17.9%
(91/509)
p=0.08,
RR=0.8
95% CI 0.62–1.02
Selected
secondary
outcomes
All outcomes were at 2 years, unless stated
All-cause
mortality
3.8%
(19/496)
2.6%
(13/509)
p=0.25
RR=0.67
95% CI 0.33–1.34
MI 9.9%
(49/496)
6.1% (31/
509)
p=0.03
RR=0.62
95% CI 0.40–0.95
CABG or repeat
PCI
12.7% (63/
496)
10.6%
(54/509)
p=0.3
RR=0.84
95% CI 0.59–1.18
Periprocedural
infarctions (from
1 year results
paper)
3.2% (16/
496)
2.4% (12/
509)
Not stated
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Patients without
event and free
from angina
64.8%
(284)
68.2%
(315)
p=0.29
Patients without information on angina status
excluded, denominator not given
EQ5D score at
1 year
73.7±16.0 74.5±15.7 p=0.65
Not reported at 2 years
Total drug-
eluting stents
used
1,359 980 p<0.001
Safety n=496 n=509 Intention to treat analysis
Total adverse
events
28.6% (142/
496)
20.8%
(106/509)
Reported as 'total events'. This includes
MACE, but additional events were not reported
in detail. Some patients may have more than
one event
CI, confidence interval; EQ5D, EuroQol-5D quality of life measure, ITT, intention to treat;
MACE, major adverse cardiac events; n, number of patients; RR, relative risk.
a The table contains information from several papers concerning the same FAME RCT.
These are: Fearon et al. (2007, study design), Tonino et al. (2009, 1 year results), Pijls et al.
(2010, 2 year results).
FAME II study
The FAME II multicentre randomised controlled trial was conducted in 28 sites in Europe and
North America and enrolled 1220 patients (De Bruyne et al. 2012; Fearon et al. 2013).
Recruitment was from May 2010 to January 2012, at which point the trial was stopped because
of a highly significant difference in the primary end point between the groups. The objective was
to determine whether FFR-guided PCI, using either PressureWire Aeris or PressureWire Certus
(with Agile Tip), with drug-eluting stents plus the best available medical therapy was superior to
the best available medical therapy alone in reducing adverse cardiac events in patients with
stable coronary artery disease.
For patients with functionally significant stenosis, the trial showed those who received PCI had
statistically significantly fewer MACE events than those who received medical treatment only.
There was no significant difference for these patients in occurrence of death or MI, but there
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were statistically significantly more urgent revascularisations for patients with functionally
significant stenosis who were treated medically rather than receiving PCI. As the study was
powered to detect a difference in MACE, non-significant results in the component outcomes may
be inconclusive. The difference in urgent revascularisations may have been influenced by
healthcare professionals being more likely to recommend PCI for patients who have only
received medical treatment to date (Boden 2012).
A summary of the trial is presented in tables 6 and 7.
The patients in this trial were already being considered for PCI, and had at least 1 vessel with
50% or greater stenosis, assessed by angiography. They were randomised to medical treatment
or PCI if functionally significant stenosis was identified using FFR measurement. It was not clear
how many would have received PCI if not enrolled in the trial.
If normal treatment for this group of patients would have been to give best available medical
treatment, FFR measurement could have helped to identify patients who would have benefitted
from treatment with PCI.
If normal treatment would have been PCI, then FFR measurement would have helped to identify
patients for whom PCI did not provide a benefit in this trial. Outcomes for patients without
functionally significant stenosis, treated medically, were not statistically significantly different from
outcomes for patients with functionally significant stenosis who received PCI.
Table 6: Summary of the FAME II trial (De Bruyne et al. 2012)
Study
component
Description
Objectives /
hypotheses
To determine whether FFR-guided PCI with drug-eluting stents plus the best
available medical therapy is superior to the best available medical therapy
alone in reducing adverse cardiac events in patients with stable coronary
artery disease
Study
design
Multicentre randomised controlled trial
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Setting 28 sites in Europe and North America, with 1220 patients. Recruitment was
from May 15 2010 to January 15 2012 at which point the trial was stopped due
to a highly significant difference in the primary end point between the PCI and
medical therapy groups.
All patients underwent FFR. Where FFR>0.8 lesions were included in a
register, and 166 were randomly selected for follow-up. Where FFR≤0.8,
patients were randomised to PCI and medical treatment, or to medical
treatment alone
Inclusion/
exclusion
criteria
Inclusion criteria:
Stable angina, or atypical / no chest pain but documented ischaemia on non-
invasive testing
At least one stenosis
≥50% in native coronary artery with diameter ≥2.5mm, supplying viable
myocardium
Eligible for PCI
Exclusion criteria:
Preferred treatment is CABG
Left main coronary artery disease needing revascularisation
Patients with a recent STEMI or non-STEMI (<1 week)
Prior CABG, contraindicated to dual anti-platelet therapy
LVEF<30%, Severe left ventricular hypertrophy,
Planned valve or aortic surgery, tortuous/calcified coronary arteries
Life expectancy <2 years, age <21, pregnancy
Variables Composite of death from any cause, non-fatal MI or unplanned urgent
revascularisation (MACE) at 2 years.
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Statistical
methods
Sample size of 816 in each group was calculated to provide 84% power to
detect a relative risk reduction with PCI of 30% for the primary end point at
24 months, alpha=0.05.
Intention to treat analysis
Mantel-Cox to calculate hazard ratios and 95% CI
Log rank test for p values
Kaplan Meier curves for primary end point.
Landmark analyses for events at landmark point of 7 days
Participants There were more men than women in the trial (coronary +medical treatment
79.6%, medical therapy 76.6%, registry 68.1%). There were significantly less
men in the registry group than in the combined randomised groups, p=0.005
There was less peripheral vascular disease in the registry group than in the
combined randomised groups (PCI+medical treatment 9.6%, medical therapy
10.7%, registry group 4.8%), p=0.03, and fewer lesions per patient
(PCI+medical treatment 1.87±1.05, medical therapy 1.73±0.94, registry group
1.32±0.59), p<0.001
Main results For the primary end point at 2 years, there was a significant difference
between the medical treatment group (12.7%) and the registry group (3.0%),
p=0.001, and also between the PCI+medical treatment group (4.3%) and the
medical treatment only group (12.7%), p<0.001. The difference between the
PCI+medical treatment group and the registry group was not significant,
p=0.61. There was a significant difference between the medical treatment only
and registry groups, p=0.001
Conclusions In patients with stable coronary artery disease and FFR≤0.8 outcomes were
better for FFR-guided PCI than for medical treatment alone
CI, confidence interval; FFR, fractional flow reserve; ITT, intention to treat; LVEF, left
ventricular ejection fraction; n, number of patients; PCI, percutaneous intervention; RR,
relative risk.
Table 7: Results of the FAME II trial (De Bruyne et al. 2012)
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PCI plus
medical
treatment
Medical
treatment
only
Registry Analysis
For PCI+MT:MT a
Randomised n=447 n=441 n=166
Efficacy n=447 n=441 n=166 ITT
Primary
outcome:
MACE at
2 years
4.3% (19/
447)
12.7%
(56/441)
3.0% (5/
166)
p<0.001
HR=0.32
95%CI 0.19–0.53
Selected
secondary
outcomes:
Death (any
cause)
0.2% (1/
447)
0.7% (3/
441)
0% (0/
166)
p=0.31
HR=0.33
95% CI 0.03–3.17
MI 3.4% (15/
447)
3.2% (14/
441)
1.8% (3/
166)
p=0.89
HR=1.05
95% CI 0.51–2.19
Urgent
revascularisation
1.6% (7/
447)
11.1%
(49/441)
2.4% (4/
166)
p<0.001
HR=0.13
95% CI 0.06–0.3
Safety n=447 n=441 n=166
Serious adverse
events
The events were listed, however the
categories overlap and it was not
possible to deduce a total number
Any
revascularisation
3.1% (14/
447)
19.5%
(86/441)
3.6% (6/
166)
p<0.001
HR=0.14
95% CI 0.08–0.26
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Stroke 0.2% (1/
447)
0.5% (2/
441)
0.6% (1/
166)
p=0.56
HR=0.49
95% CI 0.04– 5.50
Stent thrombosis 1.1% (5/
447)
0.2% (1/
441)
0.6% (1/
166)
p=0.10
HR=4.98
95% CI 0.59–42.25
CI, confidence interval; HR, hazard ratio; ITT, intention to treat; n, number of patients; RR,
relative risk.
a Additional comparisons are given in the supplementary appendix available for De Bruyne
(2012).
Dambrink (2010), Ghani (2012)
This was a randomised controlled trial carried out in a single tertiary referral centre in the
Netherlands. It used pressure wire devices from RADI Medical Systems, the previous
manufacturer of the PressureWire devices. Patients were recruited between June 2004 and
March 2007. The objective was to test the hypothesis that in patients with multi-vessel disease
successfully treated with PCI for STEMI, subsequent early FFR-guided PCI would result in
improved global left ventricular function and fewer cardiac events during follow-up compared with
conservative treatment. The trial is summarised in tables 8 and 9.
The authors concluded that an early ischaemia-guided invasive strategy prevents later PCI
procedures but does not result in a reduction in MACE at 6 months.
After 3 years of follow-up the authors concluded that FFR-guided additional revascularisation of
early FFR-guided PCI of the 'non-culprit' lesions would result in improved global left ventricular
function and fewer cardiac events during follow up compared to conservative treatment. The
non-culprit lesions are those that were not treated in the acute STEMI episode.
The strength of these conclusions was limited by the study finishing before recruitment finished,
and by combining results (re-infarction and death) in groups that were not originally planned.
Table 8: Summary of the randomised trial reported by Dambrink et al. (2010); Ghani et al.
(2012)
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Study
components
Description
Objectives /
hypotheses
To test the hypothesis that in patients successfully treated with PCI for STEMI
and with multi-vessel disease, subsequent early FFR-guided PCI would result
in improved global left ventricular function and fewer cardiac events during
follow-up compared to conservative treatment
Study design Randomised controlled trial. Patients were randomised in 2:1 ratio to invasive
treatment: FFR-guided revascularisation within 3 weeks of STEMI, or
conservative treatment
Setting Single tertiary referral centre in The Netherlands. Patients were recruited
between June 2004 and March 2007a.
Inclusion /
exclusion
criteria
Inclusion criteria: successful PCI defined by residual diameter stenosis <50%
and TIMI 3 flowb. Multi-vessel disease was defined as 1 or more significant
stenoses in at least 2 major epicardial coronary arteries, or the combination
of a side branch and a main epicardial vessel provided that they supplied
different territories. A significant stenosis was defined as a diameter stenosis
of at least 50% in luminal diameter. The reference diameter adjacent to the
lesion had to be ≥2.5 mm. Exclusion criteria: urgent indication for additional
revascularisation, age >80 years, chronic occlusion of one of the non-infarct
related arteries, prior CABG, left main stenosis of 50% or more, restenotic
lesions in non-infarcted arteries, chronic atrial fibrillation, limited life
expectancy, or other factors that made complete follow-up unlikely
Variables Primary outcome:
Ejection fraction assessed by radionuclide ventriculography at 6 months
Secondary outcomes:
Change in ejection fraction (baseline to six months)
Wall motion score, left ventricular end-systolic and end-diastolic volume and
ejection fraction at 6 months by echocardiography
MACE
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Statistical
methods
A 2-sided p value of <0.05 was considered statistically significant. A
difference of 5% in ejection fraction was considered clinically relevant. With a
standard deviation of 12%, a power of 80% and alpha of 0.05, 92 patients in
both groups were needed to detect a significant difference at the
p<0.05 level. A 10% drop-out rate was taken into account. It was anticipated
that 50% of lesions, when assessed by FFR, would warrant revascularisation,
hence the 2:1 randomisation ratio and target of 300 patients. Students t-test
was used for continuous variables. Chi-square was used for proportions
Results The study by Dambrink et al. 2010 recruited 121 patients successfully treated
with PCI for STEMI and with multi-vessel disease and randomised them to
either early (within 3 weeks of STEMI) FFR-guided PCI or conservative
treatment.
6 month follow-up:
Ejection fraction was comparable between groups (invasively treated group:
59±9% versus conservative group: 57±9%, p=0.362), and there was no
difference in MACE between invasively and conservatively treated patients
(21 versus 22%, p=0.929)
3-year follow-up:
There was no significant difference in all-cause mortality between the
invasive treatment and conservative treatment groups; 4 patients (3.4%) died
in the invasive treatment group (p=0.29). Re-infarction occurred in
14 patients (11.8%) in the invasive treatment group compared with none in
the conservative treatment group (p=0.002). Re-PCI was performed in
7 patients (8.9%) in the invasive treatment group and in 13 patients (32.5%)
in the conservative treatment group (p=0.001). There was no difference in
MACE between the 2 strategies (35.4 versus 35.0%, p=0.96
Participants Patients successfully treated with PCI for STEMI and with multi-vessel
disease.
In the invasive treatment group, PCI was performed if FFR<0.75. PCI was
performed for all severe lesions (>90% stenosis).
In the conservative treatment group, PCI was discouraged but if symptoms
occurred, ischaemia-guided revascularisation was performed based on
exercise test, dobutamine stress echocardiography or myocardial
scintigraphy
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Main results The study by Dambrink et al. 2010 recruited 121 patients successfully treated
with PCI for STEMI and with multi-vessel disease and randomised them to
either early (within 3 weeks of STEMI) invasive FFR-guided PCI or
conservative treatment. The outcome measures were global left ventricular
function and cardiac events. At 6 months follow-up, there were no statistically
significant differences between groups for ejection fraction or MACE, but
there was a higher rate of death and MI in the invasively treated group than
the conservatively treated group by ITT. At 3 years' follow-up, there were
more deaths and reinfarctions in the invasively treated group compared to the
conservatively treated group, but no difference between groups for MACE
Conclusions Authors' conclusions: an early ischaemia-guided invasive strategy prevents
later PCI procedures but does not result in a reduction of total major adverse
cardiac events at 6 months. These findings support a conservative strategy
as currently advocated by the guidelines. After 3 years of follow-up the
authors concluded that FFR-guided additional revascularisation of non-culprit
lesions early after primary PCI resulted in more deaths and/or re-infarctions
compared with a more conservative strategy of ischaemia-guided
revascularisation at a later stage
CI, confidence interval; FFR, fractional flow reserve; ITT, intention to treat; MACE, major
adverse cardiac event; MI, myocardial infarction; n, number of patients; PCI, percutaneous
coronary intervention; RR, relative risk; TIMI, thrombolysis in myocardial infarction.
a The trial was stopped before the target accrual of 300 patients was reached because of
slow recruitment and in clinical practice over time that could create an inhomogeneous study
population. It was therefore underpowered.
b Ghani et al. (2012) publication states a TIMI ≥2.
Table 9: Results of the randomised controlled trial reported by Dambrink et al. (2010) and
Ghani et al. (2012)
Invasive
treatment
group
Conservative
treatment
group
Analysis
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Randomised n=80 n=41 Randomised at 2:1 ratio
because an anticipated 50%
of FFR assessed lesions
would warrant
revascularisation
Efficacy n=80 n=41
Primary outcome:
ejection fraction
assessed by
radionuclide
ventriculography at
6 months
EF=58.9%
±9.4%
EF=56.9%
±9.3%
Assessed in 90/121 (74%) of
all patients
Difference=2%, p=0.362
Selected secondary
outcomes
Change in ejection
fraction (baseline to
6 months)
-0.2±6.7% +0.1±7% Assessed in 90/121 (74%) of
all patients
No p value reported
Wall motion score index
at 6 months
n=80
Index=1.20±0.20
n=41
Index=1.22±0.27
p=0.607
Measure of spread not
reported (presumably a mean
for a continuous variable)
End-systolic volume at
6 months
n=80
41.4±16.3
n=41
45.9±35.7
Units not reported p=0.448
End-diastolic volume at
6 months
n=80
92.7±29.5
n=41
98.9±44.1
p=0.482
Ejection fraction
(echocardiographic) at
6 months
n=80
55.7±8.2
n=41
56.3±11.8
p=0.784
MACE (6 months) 21% 22% p=0.929 ITT analysis
Death (6 months) 2.5% 0% p=0.015 ITT analysis
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MI (6 months) 14% 0% p=0.015 ITT analysis
PCI (6 months) 13% 22% p=NS ITT analysis
CABG (6 months) 6.3% 0% p=NS ITT analysis
Non-culprit-related PCI n=65a
Rate=6%
n=40
Rate=22%
p=0.017
Per protocol analysisa
Non culprit related
MACE
16% 22%
Death and MI
(6 months)
n=65a
Rate=9%
n=40
Rate=0%
p=0.079
Per protocol analysisa
MACE (6 months) n=65a
14%
n=40
22%
p=0.295
Per protocol analysisa
Death (6 months) n=65a
3%
n=40
0%
p=0.079
Per protocol analysisa
MI (6 months) n=65a
9%
n=40
0%
p=0.079
Per protocol analysisa
PCI (6 months) n=65a
9%
n=40
22%
p=0.072
Per protocol analysisa
CABG (6 months) n=65a
1.6%
n=40
0%
p=NS
Per protocol analysisa
All-cause mortality
(3 years)
n=79
4/79 (3.4%)
n=40
0/40 (0%)
n=119/121=98.3%
p=0.30
Re-PCI 15/79 (19%) 13/40 (32.5%) p=0.10
Re-PCI NCL 7/79 (8.9%) 13/40 (32.5%) p=0.001
Re-PCI CL 8/79 (10.1%) 0/40 (0%) p=0.05
CABG 12/79 (15.2%) 1/40 (2.5%) p=0.05
Re-MI 14/79 (17.7%) 0/40 (0%) p=0.002
MACE 28/79 (35.4%) 14/40 (35%) p=0.96
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Death and/or MI 16/79 (20.3%) 0/40 (0%) p=0.002
Safety n=80 n=41
Coronary dissection n=1 - Coronary dissection caused
by FFR wire
Acute vessel closure n=1 - Acute vessel closure after
FFR but before PCI leading
to CABG and death within
several days
non-STEMI n=2 - non-STEMI after FFR-guided
PCI due to side branch
occlusion
Major bleeding n=5 n=1 Defined by needing
transfusion or surgery
Subacute stent
thrombosis
n=3 - Subacute stent thrombosis
within 30 days
CI, confidence interval; EF, ejection fraction; ITT, intention to treat; n, number of patients;
NS, non-standardised; PCI-ICL, percutaneous coronary intervention, culprit lesion; PCI-
NCL, percutaneous coronary intervention, non-culprit lesion; RR, relative risk; STEMI, ST-
segment elevated myocardial infarction.
a The 65 patients are those who underwent at least one FFR measurement.
Register data
Li et al. (2013)
This retrospective cohort study included 7358 consecutive patients referred for PCI at the Mayo
Clinic, Rochester, USA between October 2002 and December 2009. It aimed to study the long-
term outcomes of FFR-guided PCI compared with PCI procedures performed without FFR. FFR
measurement used both PressureWire FFR devices and competitor products. Generally, FFR-
guided treatment proceeded to PCI if the FFR was less than 0.75, and PCI was deferred if the
FFR was greater than 0.8. For FFR values between 0.75 and 0.8, treatment was left to the
operator's judgement.
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The study is summarised in tables 10 and 11.
Unadjusted analyses showed improved outcomes at 7 years for all combinations of MACE-
related outcomes for FFR-guided PCI compared with PCI without prior FFR measurement. When
analyses were adjusted for multiple risk factors there were no differences between the groups at
7 years for any MACE-related outcome.
Unadjusted analyses of patients in the FFR-guided strategy found that patients who proceeded
to PCI had a significantly higher rate of MI at 7 years than those who did not (p=0.007). Adjusting
for multiple risk factors did not change these findings.
The authors concluded that the study supports the use of FFR for decision-making in patients
undergoing cardiac catheterisation.
Table 10 Summary of the cohort study reported by Li et al. [2013]
Study
component
Description
Objectives /
hypotheses
To study the long term outcomes of FFR guided PCI in general clinical
practice, comparing outcomes after FFR-guided PCI with outcomes after
angiography-guided PCI
Study
design
Retrospective cohort study of 7358 patients at 1 site
Setting Consecutive patients referred for PCI at the Mayo Clinic, Rochester, USA
between October 2002 and December 2009
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Inclusion /
exclusion
criteria
A register of all patients referred for coronary revascularisation at the Mayo
Clinic started in October 2002. Exclusion criteria included presentation with
ST-segment elevation MI (STEMI) or cardiogenic shock, referral for coronary
artery bypass surgery, or lack of consent
From 8942 procedures performed, 220 were excluded due to denial of
research authorisation, 1360 met exclusion criteria, and 7358 were eligible for
analysis
Patients were followed up by telephone at 3 months, 6 months, 12 months and
then annually. Information was retrieved from medical records. For patients
with deferred PCI, follow-up was by a single questionnaire and history review
Follow-up information was available in 7050 (95.8%) of patients. The median
follow-up duration was 44.9 months for PCI only, 52.5 months for FFR
PERFORM, and 48.7 months for FFR DEFER.
Variables There was no clearly stated primary outcome. Reported outcomes included
MACE, death, MI and emergency revascularisation
Statistical
methods
Students' 2-sample t-test for most continuous variables
Rank sum test for FFR comparisons
Pearson's x2 test for discrete data
Kaplan-Meier estimates to estimate survival curves, and the log-rank test to
test differences between groups
Cox proportional hazards multiple regression models to estimate association
between FFR use versus deferral on long-term outcomes
All significance tests were 2-tailed with a 0.05 significance level
Analyses were conducted using SAS 9.2
Participants Of the included 7358 patients, 6268 (85.2%) underwent PCI without FFR
assessment. In the remaining 1090 (14.8%) patients, FFR was performed.
From these 369 (33.9% of FFR) patients received PCI, and in 721 (66.1% of
FFR) PCI was deferred. In 115 (10.5% of FFR) patients PCI was performed
where FFR>0.8, and in 39 (3.6%) of patients no PCI was performed where
FFR<0.75
The PressureWire fractional flow reserve measurement system
for coronary artery disease
NICE Medtech
innovation briefing
Copyright © NICE 2014. All rights reserved. Last updated 04 February 2014 Page 34 of 54
Main results 1. Unadjusted analyses: FFR (and PCI only if indicated by FFR) strategy
versus straight to PCI strategy: the FFR group had better outcomes at 7 years
for all combinations of cardiac event outcomes. This could be due to better
selection of patients for PCI due to FFR, or it could reflect those in the FFR
group being fitter at baseline2. Unadjusted analyses: of patients who received
FFR, those who underwent PCI in response to FFR had poorer outcome at
7 years than those who had no PCI – in terms of MI only. There was no
difference for other cardiac events
3. Adjusted analyses: FFR (and PCI only if indicated by FFR) strategy versus
straight to PCI strategy: there were no longer differences between groups at
7 years for any MACE-related outcome
4. Adjusted analyses: of patients who received FFR, those who underwent PCI
in response to FFR had a poorer outcome at 7 years in terms of MI than those
in whom PCI was deferred. There was no difference in other MACE related
outcomes
Conclusions Authors' conclusions: In current practice, FFR-guided treatment is associated
with a favourable long-term outcome. The study supports the use of the FFR
for decision-making in patients undergoing cardiac catheterisation.
CI, confidence interval; ITT, intention to treat; n, number of patients; RR, relative risk; SAS,
supra-regional assay service.
The study was retrospective, so treatment decisions, including those based on FFR
diagnostic information, were made without a trial protocol. FFR may have been selectively
used in 'fitter' patients for whom a decision about whether to do PCI was more difficult.
Baseline risk factor data appear to support this.
Table 11: Results of the cohort study reported by Li et al. (2013)
PCI only All
FFR
FFR
Perform
FFR
Defer
Analysis
Randomised n=6268 n=1090 n=369 n=721
Efficacy n=6268
193 (3.1%)
lost
n=369
17 (4.6%)
lost
n=721
108 (15.0)
lost
ITT
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Primary outcome:
MACE
57% 50% p=0.016
7 year follow-up.
Unadjusted Kaplan-Meier
analysis
Selected secondary
outcomes: Mortality
32% 21% p<0.001
7 year follow-up.
Unadjusted Kaplan-Meier
analysis
MI 15% 8% p<0.001
7 year follow-up.
Unadjusted Kaplan-Meier
analysis
Mortality or MI 41% 26% - - p<0.001
7 year follow-up.
Unadjusted Kaplan-Meier
analysis
Repeat
revascularisation
36% 35% - - p=0.97
7 year follow-up.
Unadjusted Kaplan-Meier
analysis
MI - - 12% 6% 7 year follow-up.
Unadjusted Kaplan-Meier
analysis
7 year follow-up. Adjustedb Cox multivariable model
Analysis
MACE HR (All FFR:PCI) 1.01 (95% CI 0.89–1.14),
p=0.93
Death HR (All FFR:PCI) 0.89 (95% CI 0.73–1.10),
p=0.28
MI HR (All FFR:PCI) 0.79 (95% CI 0.26–0.82),
p=0.12
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Death / revascularisation HR (All FFR:PCI) 1.003 (95% CI 0.88–1.14),
p=0.96
Death / MI HR (All FFR:PCI) 0.85 (95% CI 0.711.01),
p=0.06
MACE HR (FFR-DEFER:FFR-PERFORM) 0.97 (95% CI
0.77-1.23), p=0.81
Death HR (FFR-DEFER:FFR-PERFORM) 0.84 (95% CI
0.56–1.24), p=0.37
MI HR (FFR-DEFER:FFR-PERFORM) 0.46 (95% CI
0.26–0.82), p=0.008
Death / revascularisation HR (FFR-DEFER:FFR-PERFORM) 1.002 (95%
CI 0.78–1.27), p=0.98
Death / MI HR (FFR-DEFER:FFR-PERFORM) 0.73 (95% CI
0.52–1.01), p=0.06
Safety n=6268 n=369 n=721
CI, confidence interval; FFR, fractional flow reserve; ITT, intention to treat; n, number of
patients; RR, relative risk.
a This was the only outcome between FFR-PERFORM and FFR-DEFER that reported
significance.
b Adjusted for age, sex, body mass index, smoking history, chronic heart failure on
presentation, diabetes, hypertension, hypercholesterolaemia, primary symptom, recent MI,
prior PCI, prior CABG, history of MI, heart failure, cerebral vascular disease, peripheral
artery disease, chronic obstructive pulmonary disease, renal dysfunction, presence of
tumour/lymphoma/leukaemia, metastatic cancer, ejection fraction ≤40%, ejection fraction
unknown, level of stenosis in each coronary vessel (right coronary artery, left anterior
descending, left circumflex, left main coronary artery).
Most of the results are presented in the paper graphically, and without the information
needed to present them numerically.
The PressureWire fractional flow reserve measurement system
for coronary artery disease
NICE Medtech
innovation briefing
Copyright © NICE 2014. All rights reserved. Last updated 04 February 2014 Page 37 of 54
Ongoing clinical trials
Ten ongoing or in-development studies using FFR as a decision tool for treatment of coronary
artery disease were identified, including the UK-based RIPCORD trial, in the preparation of this
briefing (NCT01764334; NCT01835808; NCT01175863; NCT01132495; NCT01399736;
NCT01366404; NCT01881555; NCT01810224; NCT01070771; NCT01960933).
Costs and resource consequences
In a 2012 audit carried out by the British Cardiovascular Interventional Society, it was reported
that FFR was used in 113 centres in the UK out of a total of 178 (118 that carry out PCI, 60 that
do diagnostic angiography only). Of 241,240 diagnostic angiography procedures, 7630 included
FFR measurement (3.1%). There were also 92,445 PCI procedures, of which 6132 included FFR
(6.6%), although there was significant variation in these proportions between centres (Ludman
2013a). In a UK regional cardiology centre, 6.2% of patients (100/1621) with NSTEMI had FFR
measured over a 15 month period in 2009–10 (Carrick et al. 2011; Carrick et al. 2013). It is not
known what proportion of these procedures used either of the 2 PressureWire FFR devices.
Many centres already use devices that measure FFR, but for others (for example, diagnostic-
only centres) additional training and new protocols would be needed. Competency-based training
for interventional cardiologists and support staff is provided by the manufacturer. This is included
in the cost of the device and depends on the needs of the centre.
The PressureWire Aeris is claimed to be compatible with 'all major hemodynamic recording
systems' so it should be suitable for most cardiac catheterisation laboratories with systems that
have FFR capability. Proprietary monitoring systems are needed for the PressureWire Certus
(with Agile tip).
Measuring FFR takes an additional 5–20 minutes during angiography or PCI.
FFR measurements during PCI are reimbursed in the NHS in England via the Payment by
Results tariff and are covered by Health Resource Group (HRG) code EA49Z. In the
2013–14 tariff, this is £3262 for elective procedures and £4440 for non-elective procedures. In
the 2014–15 tariff, FFR when used with arteriography only will be covered by HRG code EA35Z.
The tariff values for EA35 in 2014–15 will be £2092 for elective procedures and £3393 for non-
elective procedures.
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Four published economic analyses have been identified, all of which used PressureWire FFR
devices.
Fearon et al. (2003)
Fearon et al. (2003) created a decision tree model for patients with chest pain in whom
intermediate lesions were detected during angiography. The authors reported that FFR-guided
stenting during angiography was US $3830 cheaper than stenting all patients and US
$1795 cheaper than deferring PCI until a nuclear perfusion stress test is conducted. All
3 strategies had a similar quality-adjusted survival, although the quality-adjusted life year (QALY)
for the stenting strategy was slightly lower than that for the FFR strategy. Although the authors
state that in the US, PCI is often delayed for non-invasive testing after intermediate lesions are
detected, it is not known whether this represents current practice in the UK. It is also unlikely that
a strategy of stenting all intermediate lesions would be ethical because of the additional risk of
implanting a stent.
Fearon et al. (2010), FAME
Fearon et al. (2010) conducted an economic analysis using resource data and outcomes from
the FAME international multicentre randomised controlled trial. This study used international data
but was conducted in the context of the US healthcare system. A population of 1005 patients
with multi-vessel coronary artery disease who were indicated for PCI were randomised to either
angiography-guided PCI or FFR-guided PCI. Patient utility was determined using survival and
quality of life measures at 1 month and 1 year. FFR-guided PCI was reported to be less costly
than angiography-guided PCI for both the index procedure (US $13,182 ±US $9667 versus US$
14,878 ±US $9509) and the total 1 year costs (US$14315 ±US $11,109 compared with US
$16,700 ±US $11,868). Despite the wide variation in values these differences were highly
statistically significant (p<0.0001) and robust to bootstrap simulations (cost saving in 91% of
simulations). Ninety per cent of the costs were incurred during the index procedure and were
primarily dependent on the costs of drug-eluting stents, cardiac unit bed days and the FFR
devices (US $650 each).
Baseline utility was slightly higher in the FFR-guided group (significance not reported) and this
difference was corrected for by offsetting (half the difference was added to the angiography-
guided group and half was subtracted from the FFR-guided group). Offset utility increased at
1 month and remained stable at 1 year for both groups and was not statistically significantly
different between the groups (p=0.2 at 1 year). These results should be interpreted with caution
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given that the patient population was pre-determined to receive PCI for 2 or 3 lesions. The use of
FFR-guided PCI was highly likely to reduce the number of stents used and the cost of the
PressureWire FFR devices is US $1450 less than the cost of the drug-eluting stent (Hoole et al.
2011).
The PressureWire device was cost effective for the group of patients in whom 2 or more lesions
were already determined by angiography to be treated with PCI. The cost saved by reducing the
number of stents in some patients was greater than the cost incurred by using PressureWire
FFR devices on all of the patients.
Hoole et al. (2011)
Hoole et al. (2011) conducted a retrospective analysis of 100 intermediate lesions, of which
50 had an FFR of greater than 0.80, in a Canadian general hospital. Three independent
interventional cardiologists blinded to the FFR value and actual treatment provided a theoretical
treatment plan. 7 fewer stents were used with an angiography-guided decision compared with
FFR values. The authors indicated that this reduction in the number of stents plus the additional
cost of the PressureWire FFR device would result in the FFR-guided strategy being cost-
incurring with respect to angiography guidance. However, this is a simplistic analysis only
comparing the technology costs during the index procedure and ignoring any health and
resource outcomes from not using stents.
Fearon et al. (2013), FAME II
Fearon et al. (2013) conducted an economic analysis from a US perspective using resource data
and outcomes from the FAME II trial. A population of 888 patients with stable angina and
coronary artery disease for whom PCI was appropriate and who had an FFR of less than
0.80 were randomised to either FFR-guided PCI plus medical therapy or medical therapy only.
Patient utility was determined using quality of life measures at 1 month and projected assuming a
linear decline to baseline over 3 years (as the trial was stopped early). FFR-guided PCI incurred
costs with respect to medical therapy for the initial hospitalisation (US $9927 compared with US
$3900, p<0.001), primarily as a result of the PCI procedure. The cost difference reduced over the
following year, primarily as a result of a higher rate of revascularisations in the medical therapy
arm, but were still significantly higher in the FFR strategy arm (US $12,646 compared with US
$9763, p<0.001).
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Change in patient utility from baseline to 1 month was significantly higher in the FFR arm
compared with medical treatment (0.054 compared with 0.001 respectively, p<0.0001). If these
utility differences declined linearly over 3 years and costs beyond 1 year did not change, the
incremental cost-effectiveness ratio (ICER) of FFR compared with medical therapy was
determined to be US $36,000/QALY. This value was below a maximum acceptable ICER of US
$50,000/QALY in 80% of bootstrap simulations.
These results should be interpreted with caution as the patient population was defined as
patients with 'significant myocardial ischaemia caused by a coronary lesion amenable to PCI'.
NICE clinical guideline 126 states that, for patients whose angina symptoms are not controlled by
medical treatment, angiography and additional functional testing should be considered. It is not
clear if the patients in this study had poorly controlled symptoms, although they did have
angiographically demonstrated stenosis and PCI was considered appropriate for them. A
possible interpretation is that some patients randomised to medical treatment were undertreated,
as they would have received PCI if not in the trial.
Economic analyses relevant to NHS use
Bornstein et al. (2011), Siebert et al. (2011a) and Siebert et al. (2011b) conducted economic
analyses using data from the FAME study in the context of the healthcare systems of several
European countries, including the UK. These studies were only reported as conference abstracts
and so provide only a small amount of information. Cost savings in Germany, UK and Italy are
reported as ranging from 300–600 Euros per patient if an FFR-guided strategy was used in
comparison to angiography-guided PCI in patients already indicated for PCI. As in Fearon et al.
(2010) these figures do not necessarily represent the use of FFR-guided decision-making in
patients with angina whose stenosis status is unknown and in whom suitability for PCI is
undetermined.
No published economic analyses based in the UK were identified.
Strengths and limitations of the evidence
The evidence comes from 3 large multicentre randomised controlled trials, 1 single centre
randomised controlled trial and 1 large registry. This is a strong evidence level compared with
many other medical technologies.
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In all of the randomised controlled trials neither clinicians nor patients were blinded to treatment,
although in some an adjudication panel that considered adverse events was blinded to
treatment. Blinding is frequently very difficult to achieve in trials of medical devices. The single-
centre trial did not recruit the full number of patients and was underpowered, meaning that a
finding of no significant difference was inconclusive.
In some instances, differences between the treatment arms did not reach statistical significance
(at p<0.05) when data were analysed using the planned method. When outcomes are re-defined,
differences may appear to reach statistical significance. There is an increased likelihood of
detecting a difference between the arms purely by chance (type I error) associated with carrying
out multiple statistical tests on the same data, but the authors did not correct for this. As such,
results for redefined outcomes that appear to reach statistical significance (at p<0.05) should be
interpreted with caution.
A key consideration for all the trials is to understand the context of current care pathways in the
NHS and the setting for the trial. The interpretation of the results depends on the assumptions
about the treatment the patients would have received had they not been participating in a trial,
and if the same patients would have received that treatment within the NHS.
There were many more men recruited to the trials than women, reflecting disease prevalence.
However, Kim et al. (2012) addressed this in a reanalysis of the FAME data.
The register data included information from procedures carried out with both PressureWire FFR
devices and other guidewire devices with FFR capability.
Relevance to NICE guidance programmes
The use of the PressureWire fractional flow reserve devices is not currently planned into any
NICE guidance programme.
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Search strategy and evidence selection
Search strategy
Medline (1946 to present) was searched with the following strategy on 24th October 2013.
1. exp Coronary Restenosis/
2. exp Coronary Stenosis/
3. exp Coronary Disease/
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4. exp Coronary Artery Disease/
5. exp Myocardial Ischemia/
6. exp Acute Coronary Syndrome/
7. exp Angina Pectoris/
8. exp Myocardial Infarction/
9. exp Angioplasty, Balloon/
10. exp Angioplasty, Laser/
11. exp Angina, Stable/
12. exp Angina, Unstable/
13. exp Coronary Angiography/
14. exp Myocardial Revascularization/
15. exp Coronary Artery Bypass/
16. exp Percutaneous Coronary Intervention/
17. exp Angioplasty/
18. exp Stents/
19. exp Drug-Eluting Stents/
20. (coronary adj3 intervention$).tw.
21. exp Fractional Flow Reserve, Myocardial/
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22. fractional flow reserve.tw.
23. FFR.tw.
24. (pressure adj3 (wire or guidewire or catheter$ or sensor)).tw.
25. (radi adj2 press$).tw.
26. (radi adj2 wire$).tw.
27. exp Random Allocation/
28. exp Randomized Controlled Trials as Topic/
29. exp Randomized Controlled Trial/
30. (randomi#ed adj5 trial).ti,ab.
31. (randomi#ed adj5 study).ti,ab.
32. randomly allocated.tw.
33. (allocated adj2 random$).tw.
34. exp Meta-Analysis/
35. exp Meta-Analysis as Topic/
36. meta analy$.tw.
37. metaanaly$.tw.
38. (systematic$ adj (review$1 or overview$1)).ti,ab.
39. (Cochrane adj2 review).mp.
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40. or/1-20
41. or/21-26
42. or/27-39
43. and/40-42
44. 43
45. limit 44 to english language
46. limit 45 to humans
47. limit 46 to year='2003 -Current"
The initial search was not restricted to randomised controlled trials and systematic reviews and
returned over 1000 hits in Medline and over 1700 hits in Embase. It became apparent that
papers could not be quickly sorted by title and abstract, as there are many papers that compare
the diagnostic accuracy of fractional flow reserve (FFR) with other techniques, use FFR as an
outcome, or as a comparator, in addition to reviews and editorials. There were also several
randomised controlled trials with large patient numbers. Therefore the formal search was
restricted to randomised controlled trials and systematic reviews when searching large
databases. The search was also restricted to after 2003, due to the availability of a good quality
systematic review published in 2005 (Medical Services Advisory Committee (MSAC) 2005).
Databases searched were MEDLINE, Embase, Cochrane Library, DARE (including CRD, NHS
EED & HTA) and PubMed. A search was completed for ongoing clinical trials.
Evidence selection
The initial search resulted in 151 entries. It was performed by 2 independent reviewers based on
title and abstract, and the following criteria:
Population: general cardiac interventions.
Intervention: FFR using PressureWire FFR devices to decide if PCI needed.
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Comparator: standard care – angiography.
Outcomes: include all reported.
The initial search resulted in 42 papers (including 1 duplicate). These were obtained as full text.
A second selection was made by one reviewer, and checked by a second reviewer.
The final selection included clinical information from 2 systematic reviews and information on
4 randomised controlled trials (in 8 papers). A further 4 papers were selected for economic
information. In addition 1 systematic review and 1 retrospective registry analysis were identified
informally and were included.
Table 12: Papers included in systematic reviews
Study Paper Raman 2013 TEC 2011 MSAC 2005
FAME Fearon et al. (2010) ?
FAME Pijls et al. (2010) ? ?
FAME Tonino et al. (2009) ? ?
Wongpraparut et al. (2005) ? ?
Muramatsu et al. (2002) ?
FAME Nam et al. (2010) ?
FAME II De Bruyne et al. (2012) Excluded
DEFER Pijls et al. (2007) Excluded ?
DEFER Bech et al. (2001a) - ? ?
- Chamuleau et al. (2002) ?
- Legalery et al. (2005) ?
- Lindstaedt et al. (2006 ?
- Leesar et al.(2003) ?
- Bech et al. (2001b) ?
- Botman et al. (2004) ?
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- Jasti et al. (2004) ?
- Jimenez-Navarro et al. (2004) ?
- Lopez-Palop et al. (2004) ?
- Reczuch et al. (2004) ?
- Rieber et al. (2002) ?
- Bech et al. (1998) ?
- Hernandez-Garcia et al. (2001) ?
- Meuwissen et al. (2003) ?
- Ozdemir et al. (2002) ?
- Pijls et al. (1996) ?
About this briefing
Medtech innovation briefings summarise the published evidence and information available for
individual medical technologies. The briefings provide information to aid local decision-making by
clinicians, managers, and procurement professionals.
Medtech innovation briefings aim to present information and critically review the strengths and
weaknesses of the relevant evidence, but contain no recommendations and are not formal
NICE guidance.
Development of this briefing
This briefing was developed for NICE by Cedar. The Interim process and methods statement
sets out the process NICE uses to select topics, and how the briefings are developed, quality
assured and approved for publication.
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Medical Technologies Evaluation Programme, NICE
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